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Purpose/Objective: Image-guided adaptive brachytherapy 
(IGABT) is increasingly implemented as a treatment modality 
for patients with cervical cancers. The use of intercavitary 
(IC) and interstitial (IS) implants enables higher conformance 
of target dose and sparing of organs at risk (OAR). Until 
August 2014 our planning aim for HR-CTV D90 was 81 Gya/b=10 . 
Data from the EMBRACE study suggests that the planning aim 
should be above 85Gya/b=10 and in September 2014 this was 
implemted in our clinic. In this retrospective analysis data 
from 19 patients subjected to the new planning aim were 
compared with data from patients treated before September 
2014.  
Materials and Methods: Since September 2014 19 patients 
have been treated with conformal external beam 
radiotherapy (EBRT) to 50.4 Gy in 28 fractions in combination 
with IGABT, using 5 or 4 fractions with a planning aim of 5.5 
Gy or 6.5 Gy, respectively. For each brachyterapy fraction 3D 
image-guided treatment planning was performed to optimize 
the dose to the target volumes while keeping the dose to the 
OARs as low as possible. Dose-volume-histogram parameters 
for the target volumes and the OARs were recorded for each 
fraction and EQD2 total doses were calculated.The dose-
volume-histogram parameters for this patient cohort were 
compared with a patient cohort of 147 patients treated prior 
to September 2014. The latter cohort were treated with EBRT 
to a total dose of 50 Gy in 25 fractions in combination with 
IGABT, using 5 fractions with a planning aim of 5 Gy per 
fraction. 
Results: Figure 1 shows the percentage of patients that 
received HR-CTV D90>81, >85, >87, >90 Gya/b=10, with and 
without needles when the HR-CTV planning aim was 81 
Gya/b=10 and 85Gya/b=10. For the lower planning aim the fraction 
of the patients treated with HR-CTV D90>81 Gya/b=10, D90>85 
Gya/b=10, D90>87 Gya/b=10 and D90>90 Gya/b=10 was 86%, 61%, 
46% and 34%, respectively. For the higher planning aim these 
figures increased to 95%, 90%, 68% and 36%. The largest 
improvement was seen for the percentage of patients 
receiving D90>85 Gya/b=10. For the patients treated without 
needles, we were able to achieve D90>85 Gya/b=10 for all the 
patients, compared to 69% when we used the lower planning 
aim. For patients treated with needles, we were able to 
achieve D90>85 Gya/b=10 for 83% of the patients, compared to 
45% when we used the lower planning aim. Table 1 shows 
that the dose to the OARs are unchanged for both planning 
aims, which proves that we were able to increase the target 
dose without increasing the dose to the OARs. Needles were 
used in at least one fraction for 36% of the patients when the 
planning aim was 81 Gya/b=10 compared to 63%, when the 
planning aim was 85 Gya/b=10. 
 
 
 
 
 
 
 
Conclusions: When the planning aim was increased, we were 
able to increase the target dose while keeping the doses to 
the OARs unchanged. Increasing the planning aim improved 
the quality of the dose distribution. This was either achieved 
by improving the dose optimalization, by implanting more 
patients with needles or by using a higher number of needles 
per implant. 
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Purpose/Objective: The Utrecht applicator (Elekta, 
Veenendaal, the Netherlands) used in the brachytherapy (BT) 
treatment of cervixcarcinoma has the possibility to include 
up to 10 interstitial needles along with the intra-uterine and 
ovoid channels. The choice of needles and their insertion 
depth in the first fraction is based on discussion amongst 
radiation oncologists, medical physicists and RTTs, the so-
called 'expert opinion', making use of the MRI scan (without 
applicator in place) recorded in week 3 or 4 of external beam 
radiotherapy (EBRT) (pre-MRI). The purpose of this study is to 
investigate whether a pre-MRI simulation can predict more 
accurately which needles are best suited for use in the first 
BT fraction.  
Materials and Methods: For 5 patients the high risk CTV (HR-
CTV) was delineated on the pre-MRI. Using the 'applicator 
modeling' functionality the applicator was simulated on the 
MRI, the so-called 'pre-plan'. The applicator model was 
correctly placed virtually, and the needles which obviously 
entered the HR-CTV were reconstructed. Needles were then 
discarded based on a few criteria. Only needles with more 
than one active source position well within the HR-CTV were 
included. Furthermore, needle positions always avoided in 
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clinical practice due to limitations of the Utrecht applicator 
were excluded. This yielded the 'pre-plan' needle 
configuration. 
The 'pre-plan' and 'expert opinion' needle configurations were 
then compared respectively with the 'ideal' needle placement 
for the first fraction of BT. The latter was determined using a 
similar method with applicator modeling, but this time using 
the delineated MR scan of the first BT fraction (with 
applicator in place). Note that the HR-CTV delineated on the 
pre-MRI will be different to the one delineated on the MR 
scan of the first BT fraction, and also that the 'ideal' needle 
configuration will be different from the one clinically 
applied. 
The similarity of both the 'pre-plan' and the 'expert opinion' 
needle configuration as compared to the 'ideal' plan was 
quantified using Dice’s similarity coefficient. 
Fig 1. Sagittal view of applicator modeling and needle 
placement on delineated MRIs for 'pre-plan' (above) and 'ideal 
plan' (below). HR-CTV is shown in red. 
 
 
Results: The average Dice’s similarity coefficient ±1SD 
between the 'pre-plan' needles and 'ideal' needles was 0.48 ± 
0.44, while that obtained between the 'expert opinion' 
needles and the 'ideal' needles was 0.56 ± 0.32. 
Conclusions: The needles predicted by the 'pre-plan' are as 
comparable to an ideal needle placement as those predicted 
in the current 'expert opinion' scenario, but performing a 
'pre-plan' simulation of needles may well be more efficient as 
compared to expert discussion.  
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Purpose/Objective: The purpose of this retrospective 
analysis was to compare contact x-ray Brachytherapy 
(Papillon) doses and treated volumes with HDR endoluminal 
Brachytherapy for more advanced rectal cancer.  
Materials and Methods: 
Background:HDR rectal Brachytherapy is typically used as a 
boost following pre-operative RT. Patients are treated using 
our standard prescription of 10Gy in one fraction with a 
standard prescription depth of 10 mm from the surface of the 
OncoSmart flexible rectal applicator. The treatment length 
and channels to be loaded are determined by the clinician 
using 2D orthogonal imaging taken after applicator insertion. 
The applicator is reconstructed in the treatment planning 
system, where standard library plans are then used to plan 
the treatment. Source weighting is currently tapered 
symmetrically at either end of the treated length for most 
treatments. 
Methods: This analysis was undertaken retrospectively on 173 
patients treated since October 2004. Comparisons of the 
treated volume when using different treatment lengths, 
number of catheters used and source weighting were made. 
Currently 2D imaging is used in HDR Brachytherapy, so 
volumes treated for each patient prescription and treatment 
condition were calculated using an external contour in 
Oncentra Masterplan. Dose prescription points (A to H) are 
situated at the centre of the applicator, midway between 
active catheters, and 10 mm from the applicator surface. 
Results: Only patients planned using multiple catheters were 
examined as part of this analysis. The majority of patients 
were treated with 5 or 6 channels (86.7%). It can be seen 
that the volume treated increases with the number of 
treatment catheters used.  
 
 
8 patients (4.6%) were treated without source weighting. 
Using library plan data it was shown that treated volumes 
were reduced by an average of 18% when tapered source 
weighting was used. The largest volume reductions occurred 
when fewer catheters were used. The dose at the surface of 
the applicator was found to increase as the treatment length 
reduced, with an average increase of 8 Gy (range 7.7 Gy to 
8.6 Gy) as the treatment length changed from 10 cm to 4 cm. 
Dose points B to E were used as a measure of surface dose for 
the 5 catheter treatment and were situated at the applicator 
surface. 
 
Conclusions: Our results showed that the volumes treated 
with HDR endoluminal Brachytherapy were greater than those 
treated with Papillon (where <5cc is covered by the 
prescription isodose). We now modify our Brachytherapy 
treatment to use a lower number of channels (4 catheters) 
and use source weighting to reduce the volumes treated. We 
also hope to change our Brachytherapy treatment regime to 
7Gy in 3 fractions in patients with bulky residual tumour 
following EBCRT who are not suitable for a Papillon boost and 
move towards 3D planning with CT and/or MR imaging.  
   
  
